N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Metastatic Cancer
Interventions
DRUG

EMA-approved ATI based targeted therapy

All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.

Trial Locations (2)

1478

Akershus University Hospital, Lillestrøm

0379

The Norwegian Radium Hospital, Oslo

All Listed Sponsors
collaborator

The Research Council of Norway

OTHER

lead

Oslo University Hospital

OTHER

NCT02142036 - N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy | Biotech Hunter | Biotech Hunter